GlassScriptPhysician profile
Hector A Malave
NPI 1083620504
$12,849.57
in general payments reported to CMS, 2019-2025
41 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,766 · 2020: $1,567 · 2021: $2,418 · 2022: $2,003 · 2023: $1,662 · 2024: $1,813 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,075 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,075.06 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,472.05 | 2019-2025 | Farxiga, Onglyza, Lokelma |
| Amgen INC. | $1,219.88 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,168.06 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $965.27 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $868.38 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $793.98 | 2021-2025 | Verquvo, Capvaxive |
| Amarin Pharma, INC. | $790.85 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $777.16 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $671.94 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $482.80 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $482.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $470.89 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $418.95 | 2019-2025 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $384.10 | 2019-2024 | Livalo |
| Abiomed | $246.85 | 2019-2025 | Impella |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $227.57 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $170.52 | 2023-2025 | |
| Cvrx, INC. | $153.82 | 2024-2025 | Barostim Neo System |
| Abbott Laboratories | $103.78 | 2021-2024 | Mitraclip |
| Medicure Pharma INC. | $94.41 | 2021-2025 | Zypitamag |
| Azurity Pharmaceuticals, INC. | $94.38 | 2023-2025 | Edarbi, Edarbi, Horizant |
| Heartflow, INC. | $86.91 | 2022-2025 | Ffrct |
| Kiniksa Pharmaceuticals International, Plc | $81.71 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $74.79 | 2019-2025 | Praluent, Evkeeza |
| Kiniksa Pharmaceuticals, LTD. | $52.27 | 2022-2023 | Arcalyst |
| Vital Connect, INC | $51.62 | 2024-2025 | Vitalpatch Rtm |
| Arbor Pharmaceuticals, INC. | $51.13 | 2019-2020 | |
| Stryker Corporation | $49.79 | 2025 | 1788 |
| Scpharmaceuticals INC. | $44.23 | 2023-2024 | |
| Lundbeck LLC | $38.11 | 2019 | |
| Gilead Sciences, INC. | $36.71 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $35.89 | 2023 | Inpefa |
| Philips North America LLC | $32.54 | 2020 | |
| Medline Industries LP | $24.54 | 2023 | |
| Vivaquant INC, Dba Rhythm Express | $22.29 | 2025 | Rhythm Express |
| Cardiva Medical, INC. | $21.79 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Bardy Diagnostics, INC. | $20.00 | 2019 | |
| Allergan, INC. | $19.08 | 2019 | |
| Irhythm Technologies, INC. | $17.82 | 2023 | Zio Xt Patch |
| Chiesi USA, INC. | $16.88 | 2019 | |
| Kestra Medical Technology Services, INC. | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Malave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.